Systematic review and meta-analysis of antibiotic strategies for survival in patients with drug-resistant Acinetobacter baumannii infection: does quantity matter?
Article Sidebar
Main Article Content
Abstract
Background
Acinetobacter baumannii is an opportunistic pathogen frequently associated with severe hospital-acquired infections, particularly in intensive care units, and is characterized by high levels of antibiotic resistance, including to carbapenems. The rising prevalence of multidrug- and pan-drug-resistant strains poses significant therapeutic challenges and underscores the need for optimized treatment strategies to improve survival outcomes. This systematic review and meta-analysis evaluates the impact of different antibiotic treatment modalities (monotherapy versus combination) on the clinical outcome of patients with Acinetobacter baumannii infection.
Methods
This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. To find pertinent studies released up to 3 January 2025 a thorough search was done in electronic databases such as PubMed, Embase, ScienceDirect, Cochrane, EBSCOhost, Google Scholar, and Scopus.
Results
This systematic review and meta-analysis identified 20 studies for inclusion. No statistically significant overall survival difference was found (Pooled OR = 0.83, 95% CI [0.66- 1.03], p = 0.09), but subgroup analyses indicated that combination therapy markedly enhanced survival rates in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infection, APACHE II scores below 20, and bloodstream infections. Meta-regression suggested that age may adversely affect treatment efficacy. A trend favoring combination therapy was consistent across subgroups, despite some results not reaching statistical significance.
Conclusion
This systematic review and meta-analysis highlights the treatment challenges of drug-resistant Acinetobacter baumannii, particularly MDRAB, XDRAB, and CRAB strains. Combination therapy offers potential benefits in CRAB and moderate-severity cases but is not universally superior to monotherapy. Treatment outcomes are influenced by patient-specific factors such as age, infection type, and disease severity.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
1. Whiteway C, Breine A, Philippe C, Van der Henst C. Acinetobacter baumannii. Trends Microbiol 2022;30:199–200. doi: 10.1016/j.tim.2021.11.008.
2. Sharma R, Lakhanpal D. Acinetobacter baumannii: a comprehensive review of global epidemiology, clinical implications, host interactions, mechanisms of antimicrobial resistance and mitigation strategies. Microb Pathog 2025;204:107605. doi: 10.1016/J.MICPATH.2025.107605.
3. Aedh A. Prevalence of Acinetobacter infections among Intensive Care Unit’s patients in Najran. Int J Curr Res Med Sci 2017;3:122–8. doi: 10.22192/ijcrms.2017.03.05.017.
4. Bunjoungmanee P, Rattanapan K, Neamkul Y, Tangsathapornpong A, Mungkornkaew N, Kulalert P. Prevalence and risk factors of Acinetobacter baumannii infection in pediatric intensive care unit at Thammasat University Hospital. F1000Research 2024;13:1269. doi: 10.12688/f1000research.157612.1.
5. Bindu Madhavi R, Anitha D, Beena PM. Clinical and antimicrobial profile of Acinetobacter species at a tertiary care teaching hospital. J Pure Appl Microbiol 2022;16:2066–71. doi: 10.22207/JPAM.16.3.61.
6. Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol 2017;7:55. doi: 10.3389/fcimb.2017.00055.
7. Vivo A, Fitzpatrick MA, Suda KJ, et al. Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study. BMC Infect Dis 2022;22:1–12. doi: 10.1186/S12879-022-07436-W/TABLES/4.
8. Mohammed SH, Ahmed MM, Alredaa NAAA, et al. Prevalence of Acinetobacter Spp. isolated from clinical samples referred to Al-Kafeel Hospital and their antibiotic susceptibility patterns from 2017-2021. Iran J Med Microbiol 2022;16:76–82. doi: 10.30699/ijmm.16.1.76.
9. Ghasemian R, Ahanjan M, Fatehi E, Shokri M. Prevalence and antibiotic resistance pattern of Acinetobacter isolated from patients admitted in ICUs in Mazandaran, Northern Iran. Glob J Health Sci 2016;8:112. doi: 10.5539/gjhs.v8n11p112.
10. Jadhav AV, Shaikh NK. Multidrug-resistant Acinetobacter. Int J Curr Microbiol Appl Sci 2017;6:1598–603. doi: 10.20546/ijcmas.2017.609.196.
11. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 2021;10:373. doi: 10.3390/PATHOGENS10030373.
12. Wu HJ, Xiao ZG, Lv XJ, et al. Drug‑resistant Acinetobacter baumannii: from molecular mechanisms to potential therapeutics. Exp Ther Med 2023;25:1–10. doi: 10.3892/etm.2023.11908.
13. Lemos E V., de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 2014;20:416–23. doi: 10.1111/1469-0691.12363.
14. Karakonstantis S, Gikas A, Astrinaki E, Kritsotakis EI. Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients. J Hosp Infect 2020;106: 447–53. doi: 10.1016/j.jhin.2020.09.009.
15. Hernández-Torres A, García-Vázquez E, Gómez J, Canteras M, Ruiz J, Yagüe G. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality. Med Clin (Barc) 2012;138:650–5. doi: 10.1016/j.medcli.2011.06.024.
16. Huang C, Gao Y, Lin H, Fan Q, Chen L, Feng Y. Prognostic factors that affect mortality patients with Acinetobacter baumannii bloodstream infection. Infect Drug Resist 2024;17:3825–37. doi: 10.2147/IDR.S475073.
17. Shin B, Park W. Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy. J Microbiol 2017;55:837–49. doi: 10.1007/s12275-017-7288-4.
18. Papazachariou A, Tziolos RN, Karakonstantis S, Ioannou P,Samonis G, Kofteridis DP. Treatment strategies of colistin resistance Acinetobacter baumannii infections. Antibiotics 2024;13:1–15. doi: 10.3390/antibiotics13050423.
19. Taheri-Araghi S. Synergistic action of antimicrobial peptides and antibiotics: current understanding and future directions. Front Microbiol 2024;15: 1390765.. doi: 10.3389/fmicb.2024.1390765.
20. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;n71. doi: 10.1136/bmj.n71.
21. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev 2016;5:210. doi: 10.1186/s13643-016-0384-.4
22. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Cited 20252014;:2–4.
23. Higgins JPTT, Altman DG, Gotzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928. doi: 10.1136/bmj.d5928.
24. Ingle L. Cochrane RevMan. London: The Cochrane Collaboration; 2023.
25. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. London: Cochrane; 2024.
26. Borenstein M. Comprehensive meta-analysis software. In: Egger M, Higgins JPT, Smith GD, editors. Systematic reviews in health research: meta‐analysis in context, 3rd.ed. John Wiley & Sons, Inc.;2022.pp.535-48. https://doi.org/10.1002/9781119099369.ch27.
27. Kalin G, Alp E, Akin A, Coskun R, Doganay M. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 2014;42:37–42. doi: 10.1007/s15010-013-0495-.y
28. Balkan II, Batirel A, Karabay O, et al. Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis. Indian J Pharmacol 2015;47:95–100. doi: 10.4103/0253-7613.150383.
29. Katip W, Uitrakul S, Oberdorfer P, Oberdofer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics 2020;9:1–11. doi: 10.3390/antibiotics9100647.
30. Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant acinetobacter Baumannii: a propensity score-matched analysis. Pharmaceutics 2021;13:1–9. doi: 10.3390/pharmaceutics13020162.
31. Seok H, Choi WS, Lee S, et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea. J Glob Antimicrob Resist 2021;24:429–39. doi: 10.1016/j.jgar.2021.01.018.
32. Calò F, Onorato L, De Luca I, et al. Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study. J Infect Public Health 2023;16:1485–91. doi: 10.1016/j.jiph.2023.06.009.
33. Prayag PS, Patwardhan SA, Joshi RS, Panchakshari SP, Rane T, Prayag AP. Enzyme patterns and factors associated with mortality among patients with carbapenem resistant Acinetobacter Baumannii (CRAB) bacteremia: real world evidence from a tertiary center in India. Indian J Crit Care Med 2023;27:663–8. doi: 10.5005/jp-journals-10071-24534.
34. He X, Tang J, He S, Huang X. Analysis of risk factors and different treatments for infections caused by carbapenem-resistant Acinetobacter baumannii in Shaanxi, China. BMC Infect Dis 2024;24:1130. doi: 10.1186/s12879-024-10036-5.
35. Manesh A, George MM, Palanikumar P, et al. Combination versus monotherapy for carbapenem-resistant Acinetobacter species serious infections: a prospective IPTW adjusted cohort study. Infect Dis Ther 2024;13:2351–62. doi: 10.1007/s40121-024-01042-w.
36. Tian X, Lin J, Zhou M, et al. Optimizing treatment strategies for carbapenem-resistant Acinetobacter Baumannii-associated pneumonia: a multicenter study in Chinese hospitals. Infect Drug Resist 2024;17:4403–15. doi: 10.2147/IDR.S473088.
37. Yee LJKG, Abad CLR, Cabaluna ITG, Lim JA. Outcomes of adult patients with multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia treated with monotherapy versus combination therapy in a tertiary hospital. Diagn Microbiol Infect Dis 2024;110:116481. doi: 10.1016/j.diagmicrobio.2024.116481.
38. Kara I, Yildirim F, Bilaloglu B, et al. Comparison of the efficacy of colistin monotherapy and colistin combination therapies in the treatment of nosocomial pneumonia and ventilator-associated pneumonia caused by Acinetobacter baumannii. South African J Crit Care 2015;31:51–8. doi: 10.7196/SAJCC.2015.v31i2.246.
39. Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries 2015;9:476–85. doi: 10.3855/jidc.6195.
40. Kim WY, Moon JY, Huh JW, et al. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS One 2016;11: e0150642. doi: 10.1371/journal.pone.0150642.
41. Amat T, Gutiérrez-Pizarraya A, Machuca I, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect 2018;24630–4. doi: 10.1016/j.cmi.2017.09.016.
42. Jean SS, Hsieh TC, Lee WS, Hsueh PR, Hsu CW, Lam C. Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium? Med (United States) 2018;97: :e12278. doi: 10.1097/MD.0000000000012278.
43. Niu T, Luo Q, Li Y, Zhou Y, Yu W, Xiao Y. Comparison of tigecycline or cefoperazone/sulbactam therapy for bloodstream infection due to carbapenem-resistant Acinetobacter baumannii. Antimicrob Resist Infect Control 2019;8:52. doi: 10.1186/s13756-019-0502-x.
44. Park SY, Si HJ, Eom JS, Lee JS. Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem. J Int Med Res 2019;47:5977–85. doi: 10.1177/0300060519879336.
45. Shi H, Lee JS, Park SY, Ko Y, Eom JS. Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia. Infect Drug Resist 2019;12:3925–34. doi: 10.2147/IDR.S234211.
46. Makris D, Petinaki E, Tsolaki V, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med 2018;22:67–77. doi: 10.4103/ijccm.IJCCM_302_17.
47. Savoldi A, Carrara E, Piddock LJV, et al. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies. BMC Infect Dis 2021;21:545. doi: 10.1186/s12879-021-06253-x.
48. Müderris T, Dursun Manyaslı G, Sezak N, Kaya S, Demirdal T, Gül Yurtsever S. In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Eur J Med Res 2024;29:331. doi: 10.1186/s40001-024-01885-6.
49. Ju YG, Lee HJ, Yim HS, Lee MG, Sohn JW, Yoon YK. In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii. Sci Rep 2022;12:7541. doi: 10.1038/s41598-022-11464-6.
50. Xiao D, Wang L, Zhang D, Xiang D, Liu Q, Xing X. Prognosis of patients with Acinetobacter baumannii infection in the intensive care unit: a retrospective analysis. Exp Ther Med 2017;13:1630–3. doi: 10.3892/etm.2017.4137.
51. Chen Z, Chen Y, Fang Y, et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep 2015;5:17091. doi: 10.1038/srep17091.